BiotechTube
Neurokine Therapeutics

Neurokine Therapeutics

Cambridge, United States· Est.
neurokinetp.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $19M

Overview

Neurokine Therapeutics is a preclinical-stage biotech company harnessing kinase biology to create novel treatments for CNS disorders. Operating from the biotech hub of Cambridge, Massachusetts, the company is developing a pipeline of small molecule drug candidates aimed at significant unmet medical needs in neurology. As a private entity founded in 2019, it is currently pre-revenue and focused on advancing its research and development programs. Its success will depend on validating its kinase-targeting platform and translating its discoveries into clinical candidates.

Central Nervous System (CNS) Diseases

Technology Platform

Small molecule drug discovery platform focused on modulating kinase enzymes for the treatment of central nervous system disorders.

Funding History

2
Total raised:$19M
Series A$15M
Seed$4M

Opportunities

The large and growing unmet medical need in CNS disorders presents a multi-billion dollar market opportunity.
Advances in understanding kinase biology and brain-penetrant drug design provide a timely scientific foundation for novel therapeutics.
The company's focused platform could attract partnership interest from larger pharma firms seeking to bolster neurology pipelines.

Risk Factors

High scientific risk associated with novel CNS target validation and the difficulty of designing effective, brain-penetrant small molecules.
Significant financial risk as a pre-revenue company reliant on periodic venture funding.
Intense competition from numerous established and emerging biopharma companies in the neuroscience space.

Competitive Landscape

Neurokine operates in a highly competitive landscape with numerous large pharmaceutical companies (e.g., Biogen, Roche, Eli Lilly) and biotechs pursuing various approaches to CNS diseases. Direct competitors include other companies focusing on kinase modulation for neurology, such as small molecule specialists in the neuroinflammation and neurodegeneration space. Differentiation will require demonstrating superior target selectivity, brain exposure, or efficacy in relevant disease models.

More companies in Small Molecule Drugs →More companies in United States →